Peptide Synthesis Cost Comparison — Direct SPPS versus Fragment Ligation
Labeled Peptide Peptide Fusion When a laboratory asks for the cost for peptide synthesis, two route proposals may appear to describe the same purchase. One offers direct assembly of the whole chain. Another proposes making fragments and joining them. A meaningful comparison must follow both routes to the same characterized, usable product.
Reaction count alone cannot choose the cheaper route. Direct assembly can avoid fragment-handling stages but become difficult as the chain grows. Fragment ligation can make shorter intermediates easier to manage while adding preparation, joining, purificazione, and analytical work. The relative cost depends on the sequence and on recovery through the complete process.
This guide compares two routes for a hypothetical research target. All prices remain to be quoted. The comparison is a planning exercise, not a cost estimate, a supplier ranking, or a claim that either route has been demonstrated for the example.
The target sequence is H-AGLQKSEAVGATQALGEKASVAGAQVKCLAEGAQLAGEVAKSAGTAVKQALGSEA-OH, con 55 residues and L configuration at every chiral residue. Ser42 is phosphorylated; the other serines are unmodified. Cys28 is the only cysteine and must remain a free thiol in the final product. Both backbone termini are free.
What must both quotations include?
For the teaching comparison, request 50 mg on the same explicitly defined target-peptide basis. Propose at least 95% area purity under an agreed suitable method, with evidence addressing the phosphate location and cysteine state. These are hypothetical discussion parameters, not universal quality standards. Final criteria should follow the actual assay.
Use the same final counterion specification, sample format, storage information, e risultati analitici. If acetate exchange is required, define the accompanying residual-counterion criterion and measurement before comparing quotes. The name of the desired salt does not establish how completely another counterion has been removed.
Keep both offers on the same target-amount basis. A gross powder quantity cannot silently replace the assigned amount requested here. Resolve the definition and final-form scope before calculating a cost per accepted milligram.
Also require the same scope of identity evidence. An intact mass compatible with one phosphate does not establish which of the several serines is modified. Likewise, a material containing the expected chain can differ in cysteine oxidation state or contain intermolecular species. The appropriate analytical package should address the attributes that matter to this target.
Make the molecular target, final form, analytical evidence and quantity basis explicit in both proposals. General capability descriptions do not establish a quotation for this sequence. Ask each route owner to identify exclusions rather than infer a common endpoint from similar price headings.
How do direct SPPS and fragment ligation differ?
In the direct option, the entire 55-residue chain is assembled by SPPS using a protection and release strategy compatible with the final free acid and specified modification. The proposal must include cleavage, deprotezione, purificazione, recupero, and characterization. A statement about chain assembly time is only one part of the deliverable.
IL MIT record of rapid protein chemical synthesis Produttore di peptidi etichettati provides context for direct assembly of selected long chains. It does not establish this phosphopeptide’s recovery, profilo di impurità, feasibility or price.
In the fragment option, a candidate split is between Lys27 and Cys28. Classical native chemical ligation would require residues 1–27 as a suitable C-terminal thioester and residues 28–55 with an available N-terminal cysteine. The second fragment contains the specified phosphoserine. Its terminal carboxyl must remain compatible with the final free-acid target.
Map local fragment positions before comparing scope. The proposed split makes a 27-residue first segment ending at Lys27 and a 28-residue second segment beginning at Cys28. The final target therefore retains 27 + 28 = 55 residui; joining does not intentionally insert another residue. Acetyl Hexapeptide-1 Wholesale
The requested phosphoserine is final-chain Ser42, which becomes position 15 of the second segment: 42 − 27 = 15. A quotation for a segment labeled only “phosphoserine 15” needs that reference frame. The final chain also contains Ser6, Ser20 and Ser53, so preserving the full-chain annotation prevents a local index from becoming a different modification request.
Keep both coordinate systems in the intermediate specification. Correct arithmetic does not localize the actual phosphate, but it prevents the route plan itself from silently moving the site before any material is made.
IL original native chemical ligation study describes a peptide thioester reacting with an N-terminal cysteine to form a native amide bond. The proposed junction follows that structural idea; compatibility and successful preparation of these exact intermediates remain project questions.
| Itinerario | Advantages | Limitations | Conditions favoring consideration | Verification needed |
|---|---|---|---|---|
| Direct SPPS of the 55-mer | One main chain-assembly route; avoids separate fragment joining and intermediate inventories | Accumulated incomplete reactions or difficult chain behavior can reduce recoverable target | A compatible full-chain process and workable final purification are supported | Full-chain identity, modification assignment, impurity assessment, and accepted recovery |
| SPPS fragments followed by native chemical ligation | Shorter segments can be examined separately; the native Cys28 offers a candidate junction | Requires thioester preparation, two segment recoveries, ligation, and further finishing | Fragment access and solution behavior are favorable enough to offset added operations | Segment identities, correct junction and phosphate location, thiol state, and final accepted recovery |
A useful proposal identifies the evidence behind its route choice. If the supplier has experience with a closely related sequence, ask which features match and which differ. If neither route has relevant support, a defined feasibility stage can be costed separately. Do not turn a plausible split into a guaranteed manufacturing plan.
A price for the first segment as an ordinary free carboxyl-terminal peptide is not automatically a price for the thioester required by the Glp Peptides proposed classical NCL route. Reactive-terminal preparation, its characterization and its supported handling are part of the input scope.
Likewise, the second segment must present the required N-terminal cysteine for the planned joining step. A generic fragment certificate may not answer that reactive-state question. Ask the route owner to identify the actual intermediate forms and where they are qualified.
These requirements do not imply that a particular preparation route will work or that either fragment is unstable. They identify why two visually similar fragment prices can describe different purchases. A low joining charge cannot compensate for inputs that have not been included in the quotation.
Do not add intermediate milligram quantities and call the sum the final target amount. The segments are separate molecules with their own terminal definitions, and the reactive form includes chemistry that is not simply retained as an extra group on the final chain. The route owner should state how the supplied intermediates support the promised accepted product, rather than rely on an attractive total intermediate weight.
Where can apparent savings disappear?
For direct assembly, an attractive synthesis charge may exclude extra purification, difficult isolation, or a second attempt needed to obtain the specified amount. For fragment ligation, prices for the two fragments may omit reactive-terminal preparation, intermediate analyses, joining, and final purification. Ask for a complete scope before comparing totals.
Include material consumption at every stage. A fragment produced in apparent excess is useful only if its identity, reactive state, and stability support the next operation. A ligation conversion measured in solution is not the same as the amount of purified final peptide delivered to the laboratory.
The two routes can generate different impurity problems. Direct synthesis may contain sequence-related products that are difficult to separate. Ligation can leave unreacted segments or other products associated with joining and handling. Neither impurity profile is automatically easier, and a common final HPLC percentage may conceal different analytical blind spots. Polypeptide Protein
Follow each intermediate through to the final molecular definition. The native amide junction is a connectivity requirement, and the final free-thiol requirement remains a separate attribute. Do not count completion of the joining reaction as proof of all final cysteine-state or impurity requirements.
Nor should an intermediate’s purity percentage be substituted for the final product’s result. Joining and finishing create a different analytical object. The delivered 55-mer needs evidence appropriate to its own specification, while intermediate records explain the route used to obtain it.
The most useful matched comparison states what remains to be done after each quoted subtotal. If direct assembly includes final purification while the fragment offer stops at isolated segments, compare the missing work before declaring a route cheaper. If the ligation route is still a feasibility study, preserve that status. The question is the cost and uncertainty of reaching the same accepted endpoint, not the smallest sum of incompletely defined reaction charges.
Counterion exchange and aliquoting can also change recovery. If both proposals promise the same final form, both should include those operations and the associated measurement. If one proposal supplies bulk material requiring further work by the receiving laboratory, include that work in the comparison.
Define which route uncertainties must be resolved before a delivery commitment is meaningful. A feasibility proposal and a committed final-product offer can both be useful, but their prices refer to different obligations. Keep those scopes visible instead of assigning invented failure probabilities.
A matched RFQ and cost worksheet
Send the complete annotated target and request two proposals for the same endpoint. Ask each proposal to state the following items, using “included,” “excluded,” or a separately quoted amount rather than leaving ambiguous blanks.
| Cost or scope item | Direct SPPS proposal | Fragment-ligation proposal |
|---|---|---|
| Feasibility assessment or method development | To be quoted and scoped | To be quoted and scoped |
| Assembly and reactive-intermediate preparation | Whole-chain assembly and release scope | Both fragments, thioester preparation, and joining scope |
| Purificazione, final form, and isolation | To be quoted through final product | To be quoted through final product |
| Agreed identity and impurity evidence | Methods and deliverables to be stated | Same endpoint evidence, with additional intermediate work identified |
| Accepted target-peptide amount | 50 mg on agreed measurement basis | 50 mg on the same basis |
| Aliquots, documentazione, shipping, and applicable charges | To be quoted | To be quoted |
| Repeat-work terms and schedule assumptions | To be stated | To be stated |
Complete the RFQ with intended laboratory use, required arrival date, shipping destination, quote currency and validity, final acceptance criteria, and any confidentiality arrangement. Specify whether unused intermediates or analytical reference material are part of the requested delivery. No supplier has been contacted for this illustrative comparison.
Once responses arrive, compare total payable cost for the matched deliverable. Calculate cost per accepted milligram only after resolving differences in content assignment, excluded services, and retained testing material. If the evidence still favors neither route, choose the next feasibility experiment that resolves the most consequential uncertainty rather than selecting the lowest incomplete subtotal.
Domande frequenti: comparing peptide synthesis routes by cost
Is fragment ligation always cheaper for a long peptide? NO. Shorter segments can help, but joining and intermediate handling add work. The balance depends on the complete sequence and accepted final recovery.
Does fast automated assembly guarantee a short delivery time? NO. Purificazione, analisi, final-form preparation, and shipment remain part of the project. Ask for a schedule through accepted delivery.
Can a route change the sequence to improve yield? Only through an explicitly approved target change. Here the intended junction uses the existing Cys28 without adding a residue. A permanent tag, residual handle or altered linkage would change the endpoint and must be reviewed as such.
What makes two quotes genuinely comparable? The same molecular specification, base quantitativa, analytical endpoint, final form, delivery scope, and treatment of unresolved specifications. Resolve those terms before deciding which price represents better value for the experiment.
